15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 17 firms covering ACADIA Pharmaceuticals Inc, 14 rate it Buy or better, 3 sit at Hold, and 0 rate it Sell or worse, a strong buy consensus. Targets span $25.00 to $49.00, a moderate spread. The average target of $35.12 sits 27% above the current $27.58. Sentiment has drifted a little more constructive lately, with Sell ratings easing from 1 to 0 over recent months. On the fundamentals, the Street sees revenue growth near 16% this year and 12% next, consensus EPS building from about $0.21 next quarter toward $0.89 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS17 ratings
Strong Buy
Strong Buy00%
Buy1482%
Hold318%
Sell00%
Strong Sell00%
Based on 17 analysts giving stock ratings to ACADIA Pharmaceuticals Inc.
As of Sep, 14 of 17 firms rate ACAD a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
ACAD EPS & revenue forecast
EPS · NEXT QUARTER
$0.21
Range $0.14 – $0.26 · 14 analysts · +56% YoY
Next period, 14 analysts expect ACADIA Pharmaceuticals Inc to earn $0.21 a share (range $0.14 – $0.26), versus $0.14 a year earlier. Full-year consensus is $0.60, growing to $0.89 the year after.
REVENUE · NEXT QUARTER
$362.7M
Range $350.6M – $375.0M · 14 analysts · +17% YoY
Revenue is expected to reach $362.7M (range $350.6M – $375.0M), +17.0% year-over-year. Full-year consensus is $1.3B, rising to $1.4B next year.
Top analysts covering ACADIA Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on ACAD.
#1
JH
Jeffrey Hung
Morgan Stanley · Rank #3
Hold
$28.00+1.5% to target
Overall win rate
64%
+ Follow
#2
Jason Butler
JMP Securities · Rank #31
Buy
$36.00+30.5% to target
Overall win rate
53%
+ Follow
#3
Ami Fadia
Needham · Rank #67
Buy
$41.00+48.7% to target
Overall win rate
47%
+ Follow
#4
Joel Beatty
Baird · Rank #80
Buy
$31.00+12.4% to target
Overall win rate
48%
+ Follow
#5
Yigal Nochomovitz
Citigroup · Rank #245
Buy
$40.00+45.0% to target
Overall win rate
41%
+ Follow
ACAD stock forecast FAQ
What is ACAD's average 12-month price target?+
The 17 analysts with a live target average $35.12 for ACADIA Pharmaceuticals Inc over the next 12 months, ranging from a $49.00 high to a $25.00 low.
Is ACAD stock a Buy, Sell or Hold right now?+
The current consensus is Strong Buy. Of the 17 analyst ratings, 14 are Buy or Strong Buy, 3 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for ACAD?+
The Street-high target is $49.00 (UBS), and the Street-low is $25.00 (Oppenheimer). The average of all 17 active targets is $35.12.
How many Wall Street analysts cover ACAD?+
17 analysts have an active rating on ACADIA Pharmaceuticals Inc, and 17 firms carry a live 12-month price target.
Who is the most accurate analyst covering ACAD?+
Among analysts who currently cover ACAD, Jeffrey Hung of Morgan Stanley has the strongest overall Quantellect track record (Rank #3). Their current call is Hold with a $28.00 target.
What is ACADIA Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.21 per share (range $0.14 – $0.26) across 14 analysts. Full-year EPS is projected at $0.60, rising to $0.89 the following year.
How much revenue is ACADIA Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $362.7M (range $350.6M – $375.0M). Full-year revenue is projected at $1.3B, growing to $1.4B next year.
Have analysts been upgrading or downgrading ACAD lately?+
As of Sep, 14 of 17 firms rate ACAD a Buy (3 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their ACAD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
